Retraction Watch: “Extensively lined paper on ranitidine-cancer hyperlink retracted.”
Carcinogenesis: “Oral consumption of ranitidine will increase urinary excretion of N-nitrosodimethylamine.”
Carcinogenesis: “Retraction to: Oral consumption of ranitidine will increase urinary excretion of N-nitrosodimethylamine.”
Natural Course of Analysis and Growth: “Ranitidine-Investigations into the Root Trigger for the Presence of N-Nitroso-N,N-dimethylamine in Ranitidine Hydrochloride Drug Substances and Related Drug Merchandise.”
The Oncologist: “The Discovering of N-Nitrosodimethylamine in Widespread Medicines.”
medRxiv: “Ranitidine use, N-Nitrosodimethylamine (NDMA)manufacturing and variations in most cancers diagnoses.”
Statista.com: “Main antacid pill manufacturers in the USA in 2019, based mostly on gross sales (in million U.S. {dollars}).”
Ivan Oransky, MD, co-founder, Retraction Watch; Distinguished Author in Residence, New York College.
David Gentle, CEO, Valisure, New Haven, CT.
Ron Najafi, PhD, president and CEO, Emery Pharma, San Francisco Bay space.
Brent Wisner, legal professional, Baum Hedlund Aristei & Goldman, Los Angeles..
Jeremy Kahn, FDA spokesperson.
FDA: “Zantac (ranitidine): Security Data—NDMA Present in Samples of Some Ranitidine Medicines.”
FDA: “Questions and Solutions: NDMA Impurities in ranitidine (generally generally known as Zantac).”
Joe Waechter, legal professional, Morgan & Morgan.
Source link
